Drug safety

Our top priority is that our medicinal products are safe.


  • continuous improvements regarding the use,
  • comprehensive information about our medicinal products and
  • tracking and following up on adverse reactions

are an important concern for us.

On these pages, you will find important information about drug safety. If you have any further questions about the use of our medicinal products or adverse drug reactions (ADRs), please do not hesitate to ask us.

We are legally obliged to - and in the interest of a high degree of drug safety strive to - assess each case of a suspected adverse drug reaction. For this purpose, it is required that you precisely document your observations whenever adverse drug reactions occur and that you furthermore tell us which medicines you are taking and which underlying and concomitant disorders you have.

The purpose of the following information is to provide you with further instructions and support

Which adverse drug reactions (ADRs) are important and must be reported?

Depending on whether an adverse drug reaction is labelled in the Patient Information Leaflet, we differentiate between expected and unexpected drug reactions. In general, we are interested in any ADR reports, and in particular those that are not labelled in the Patient Information Leaflet or have an unexpectedly severe course.

However, please do note that reporting the ADR must not replace a visit to the doctor under any outcome.

Whom can I contact in a case of an adverse drug reaction?

You can report suspected adverse reactions directly to us:

APOGEPHA Arzneimittel GmbH
Drug Safety Department
E-Mail: Pharmacovigilance

or via the national reporting system to the

Federal Institute for Drugs and Medical Devices
Pharmacovigilance Department:
Bundesinstitut für Arzneimittel und Medizinprodukte
Abt. Pharmakovigilanz
Kurt-Georg-Kiesinger Allee 3
D-53175 Bonn

Website: www.bfarm.de


Please fill at least all field marked with an *

Patient Data
Adverse Event (AE)
Drugs (suspect drug and concomitant drugs)
I herewith agree that this data may be transmitted to the responsible authorities in the context of drug safety obligations of the marketing authorisation holder (MAH)
press the button when prompted:

1Verkauf, Bestellung, Verfügbarkeit

2Nebenwirkungen, Reklamationen

3Medizinische Anfragen